Study On The Effect Of Ayurvedic Medicines And Uttarabasti Therapy in Improving Fertility in Women with PCOS Related Infertility Through Gene Expression Study

EFFICACY OF ORAL ADMINISTRATION OF TRIPHALA CHOORNA, KANASHATAHWADI KASHAYA ALONG WITH SHATAPUSHPA TAILA UTTARABASTI ON ENDOMETRIAL RECEPTIVITY ASSESSED BY GENE EXPRESSIONS IN WOMEN WITH POLYCYSTIC OVARIAN SYNDROME RELATED INFERTILITY: A SINGLE ARM OPEN LABELLED CLINICAL TRIAL - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2026/06/112744

Enrollment

Registered

2026-06-15

Start date

Unknown

Completion date

Unknown

Last updated

2026-06-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N830- Follicular cyst of ovary

Interventions

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Married patients in the age group of 18-40 years. 2. Diagnosed cases as per Rotterdam criteria (2018)-ASRM (American Society for Reproductive Medicine) criteria for PCOS. 3. Patients fall under the categories of Overweight (BMI- 25.0 -29.9 kg/m2) and Class 1 Obesity (BMI- 30.0 34.9 kg/m2). 4. Patients willing to give written informed consent by themselves. 5. Patients eligible for Uttarabasti Karma.

Exclusion criteria

Exclusion criteria: 1. Patients of Age Less Than 18 years and Greater Than 40 years. 2. Lactating mothers. 3. Patients with history of uncontrolled hypertension (Systolic BP Greater than 160 mmhg & Diastolic BP Greater than 100mmhg), uncontrolled Diabetes Mellitus (FBS Greater than 160 mg/dl). 4. Patients having Hypothyroidism. 5. Organic lesions of reproductive tract like Tuberculosis, Carcinoma, congenital deformities and Sexually Transmitted Diseases, Fibroid Uterus. 6. Endocrinopathies like Androgen Secreting Tumors, Cushing Syndrome, Hyperprolactinemia. 7. Unmarried patient. 8. Patients who are taking hormonal or GnRH treatments. 9. Systematic Disorders like Severe cardiac, pulmonary, hepatic, renal diseases or central nervous system disorders. 10. Patients who are Known case of Premature ovarian failure. 11. Patients not willing to participate in study.

Design outcomes

Primary

Measure	Time frame
The intervention selected in this study is expected to show effects on endometrial receptivity in PCOS, including gene expression patterns and morphology of the endometrium.Timepoint: 120 days (Four consecutive menstrual cycles)	—

Secondary

Measure	Time frame
improving all the clinical features of the disease, based on various analytical parameters.Timepoint: 120 days (Four consecutive menstrual cycles)	—

Countries

India

Contacts

Public ContactDr Shilpa B Donga

institute of teaching and research in ayurveda,jamnagar

drshilpadonga@yahoo.com9825646796

Outcome results